^
    1d
    Prognostic impact of concomitant genomic alterations in patients affected by FGFR2-positive locally advanced unresectable or metastatic cholangiocarcinoma treated with pemigatinib as second or further line of systemic treatment: molecular analysis of the real-world Italian PEMIREAL and French PEMIBIL cohort studies (AIOM 2024)
    Our results seem to confirm the negative prognostic role in terms of PFS of GA in BAP1 and CDKN2A genes in patients affected by locally advanced or metastatic FGFR2-positive CCA treated with pemigatinib in a real-world setting.
    Clinical • Real-world evidence • Real-world • Metastases
    |
    TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    FGFR2 fusion • CDKN2A mutation
    |
    FoundationOne® CDx
    |
    Pemazyre (pemigatinib)
    1d
    Advanced Intrahepatic Cholangiocarcinoma (iCCA): Investigating Co-Molecular Alterations (AIOM 2024)
    The FGFR and IDH-1 pathways are the primary targets for therapy, with FGFR-2 and IDH-1 inhibitors, such as Pemigatinib and Ivosidenib respectively, already available on the market. This prospective study validates the prevalence of mutations documented in the literature and underscores the significance of NGS in presenting supplementary therapeutic avenues. Moreover, we demonstrated the role of other potential targets co-expressed with FGFR2 or IDH1 which could represent a crucial opportunity for novel combinations or sequences therapies.
    BRCA Biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • MTAP (Methylthioadenosine Phosphorylase) • BAP1 (BRCA1 Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NTRK (Neurotrophic receptor tyrosine kinase) • CA 19-9 (Cancer antigen 19-9)
    |
    TP53 mutation • KRAS mutation • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • CDKN2A mutation • BAP1 mutation • FGFR2 expression • FGFR2b expression
    |
    FoundationOne® CDx
    |
    Pemazyre (pemigatinib) • Tibsovo (ivosidenib)
    2d
    FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development. (PubMed, J Korean Med Sci)
    Among these therapies, erdafitinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor for specific FGFR2 and FGFR3 alterations, is the only targeted therapy approved till now...Ongoing investigations exist on its use in non-muscle-invasive BC and in combination with drugs such as enfortumab vedotin in mUC...This review emphasizes the importance of FGFR inhibition in UC and the optimization of its use in clinical practice. Moreover, it underscores the ongoing efforts to evaluate combination strategies and early treatment testing to enhance the effectiveness of targeted therapies for UC.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • RB1 (RB Transcriptional Corepressor 1)
    |
    TP53 mutation • FGFR2 mutation • FGFR3 mutation
    |
    Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    3d
    The Prognostic Value and Immunotherapeutic Characteristics of GFPT2 in Pan-cancer. (PubMed, Comb Chem High Throughput Screen)
    Collectively, GFPT2 is potentially useful as a biomarker for prognostic prediction and immune infiltration in a variety of malignancies ,and could lead to exciting new approaches to personalized oncotherapy.
    Journal • Tumor mutational burden • PARP Biomarker • IO biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • GFPT2 (Glutamine-Fructose-6-Phosphate Transaminase 2)
    |
    Lynparza (olaparib) • Lenvima (lenvatinib) • Tasigna (nilotinib)
    3d
    Neoadjuvant Pemigatinib as a Bridge to Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma with FGFR2 Rearrangement. (PubMed, Am J Transplant)
    He underwent an uncomplicated LDLT (including an uncomplicated donor surgery) and at one year follow-up is without evidence of disease recurrence. We believe this is the first report of LDLT for this indication.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 rearrangement
    |
    Pemazyre (pemigatinib)
    3d
    Establishment and characterization of mouse metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma organoids. (PubMed, Sci Rep)
    Transcriptomic analysis of these resistant organoids identified key pathways related to KRAS signaling, inflammation, and epithelial-mesenchymal transition (EMT), revealing potential targets for overcoming Lenvatinib resistance. This study provides valuable insights into MASH-related HCC progression and drug resistance, offering a model for further therapeutic research.
    Preclinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Lenvima (lenvatinib)
    3d
    EPOC2001: An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, National Cancer Center Hospital East | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Aug 2026
    Enrollment closed • Trial primary completion date
    |
    Keytruda (pembrolizumab) • docetaxel • 5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin • levoleucovorin calcium
    3d
    Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (clinicaltrials.gov)
    P2, N=603, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    4d
    Comparative Outcome Analysis of Lenvatinib Versus Sorafenib for Recurrence of Hepatocellular Carcinoma After Liver Transplantation. (PubMed, Transplantation)
    Our findings suggest lenvatinib is a valuable treatment option for patients with HCC recurrence after LT.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    sorafenib • Lenvima (lenvatinib)
    4d
    Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=35, Completed, Vanderbilt-Ingram Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4) • FGF23 (Fibroblast Growth Factor 23)
    |
    HER-2 negative • FGFR1 amplification • FGFR3 amplification • FGFR4 amplification • FGFR amplification
    |
    Ibrance (palbociclib) • Balversa (erdafitinib) • fulvestrant
    8d
    An open, multicenter, randomized controlled study of the efficacy and safety of lenvatinib and tirellizumab adjuvant therapy in patients with high-risk relapsing factors for hepatocellular carcinoma (ChiCTR2400090517)
    P3, N=328, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New P3 trial
    |
    AFP (Alpha-fetoprotein)
    |
    Lenvima (lenvatinib)
    8d
    An open-label, single-center, prospective study of transarterial chemoembolization (TACE) combined with Adabelimab and lenvatinib mesylate for unresectable advanced hepatocellular carcinoma. (ChiCTR2400090801)
    P2, N=30, Not yet recruiting, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital); The First Affiliated Hospital of Nanjing Medical University
    New P2 trial • Metastases
    |
    Lenvima (lenvatinib)
    8d
    A clinical study of transcatheter arterial chemoembolization (TACE) combined with tirilizumab and lenvatinib in the treatment of pancreatic cancer hepatic metastases (ChiCTR2400089874)
    P2, N=38, Recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial
    |
    Lenvima (lenvatinib)
    8d
    A prospective, open, multi-cohort study of cardonilimab combined with lenvastinib in renal cell carcinoma (ChiCTR2400090483)
    P2, N=46, Not yet recruiting, Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Lenvima (lenvatinib)
    8d
    Adebrelimab combined with irinotecan liposome, 5-fluorouracil, calcium folinate ± lenvatinib in first-line treatment of advanced intrahepatic cholangiocarcinoma:a prospective clinical study (ChiCTR2400089273)
    P2, N=68, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New P2 trial • Metastases
    |
    5-fluorouracil • Lenvima (lenvatinib) • leucovorin calcium • Ariely (adebrelimab)
    8d
    An open-label and multicenter Phase Ⅰ Clinical Study to Evaluate the Safety and Efficacy of SYS6010 in combination with Enlonstobart and Simmitinib in patients with advanced esophageal cancer (ChiCTR2400089300)
    P1, N=60, Not yet recruiting, The First Affiliated Hospital of Henan University of Science and Technology; The First Affiliated Hospital of Henan University of Science and Technolo
    New P1 trial • Combination therapy • Metastases
    |
    Enshuxing (enlonstobart) • simmitinib (SYHA1817)
    8d
    Efficacy and safety of adebrelimab combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma: a randomized controlled open-label phase II study (ChiCTR2400080080)
    P2, N=36, Recruiting, The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lenvima (lenvatinib) • Ariely (adebrelimab)
    11d
    Enhancing transcription-replication conflict targets ecDNA-positive cancers. (PubMed, Nature)
    In a gastric cancer model containing FGFR2 amplified on ecDNA, BBI-2779 suppresses tumour growth and prevents ecDNA-mediated acquired resistance to the pan-FGFR inhibitor infigratinib, resulting in potent and sustained tumour regression in mice. Transcription-replication conflict emerges as a target for ecDNA-directed therapy, exploiting a synthetic lethality of excess to treat cancer.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 amplification
    |
    Truseltiq (infigratinib)
    11d
    Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    12d
    Lenvatinib-resistant hepatocellular carcinoma promotes malignant potential of tumor-associated macrophages via exosomal miR-301a-3p. (PubMed, Ann Gastroenterol Surg)
    Activation of Nrf2 signaling by LR HCC cell-derived exosomal miR-301a-3p skewed the transformation of macrophages to the M2 phenotype. Our study provides new findings on the role of miR-301a-3p, suggesting it is a promising therapeutic target to improve HCC lenvatinib resistance.
    Journal
    |
    PTEN (Phosphatase and tensin homolog)
    |
    Lenvima (lenvatinib)
    13d
    Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study. (PubMed, Cancer Immunol Immunother)
    The combination regimen demonstrated promising efficacy in treating unresectable HCC, accompanied by manageable safety profiles. Furthermore, the results of this investigation suggest that AFP holds promise as predictive biomarkers for this treatment strategy.
    Retrospective data • Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
    |
    AFP (Alpha-fetoprotein)
    |
    Tyvyt (sintilimab) • Lenvima (lenvatinib)
    13d
    PLAS: Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, National Cancer Center, Japan
    New P2 trial
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    13d
    Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Texas Southwestern Medical Center | Trial primary completion date: Aug 2024 --> Dec 2024
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    13d
    Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=39, Completed, Nanfang Hospital, Southern Medical University | Recruiting --> Completed
    Trial completion
    |
    Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • oxaliplatin
    13d
    PEMMELA: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, The Netherlands Cancer Institute | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    |
    TMB (Tumor Mutational Burden) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    13d
    BAIAP2L2 promotes the malignancy of hepatocellular carcinoma via GABPB1-mediated reactive oxygen species imbalance. (PubMed, Cancer Gene Ther)
    BAIAP2L2 inhibits the levels of reactive oxygen species (ROS) by regulating GABPB1, thereby promoting cancer properties in HCC and reducing the sensitivity of HCC to lenvatinib. In summary, this study elucidates the role and underlying mechanism of BAIAP2L2 in HCC, providing a potential biomarker and therapeutic target for this disease.
    Journal
    |
    BAIAP2 (BAR/IMD Domain Containing Adaptor Protein 2)
    |
    Lenvima (lenvatinib)
    14d
    N6-Methyladenosine (m6A) modification activates serine synthesis pathway to mediate therapeutic resistance in liver cancer. (PubMed, Mol Ther)
    STM2457 treatment attenuated the serine synthesis pathway, induced oxidative stress, and sensitized HCC cells to sorafenib and lenvatinib treatments. In conclusion, our findings suggest that targeting m6A could be a potential therapeutic strategy for HCC treatment.
    Journal
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PHGDH (Phosphoglycerate Dehydrogenase) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • METTL3 (Methyltransferase Like 3)
    |
    MYC overexpression • MYC expression
    |
    sorafenib • Lenvima (lenvatinib)
    17d
    The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma. (PubMed, J Exp Clin Cancer Res)
    On this basis, the present review aims at providing an overview of recently explored connections between the FGF/FGFR system and c-Myc oncoprotein, sustaining the therapeutic potential of targeting the FGF/FGFR/c-Myc axis in MM by using inhibitors targeting FGF ligands or FGF receptors. Importantly, the provided findings may represent the rationale for using FDA approved FGFR TK inhibitors (i.e. Pemigatinib, Futibatinib, Erdafitinib) for the treatment of MM patients presenting with an aberrant activation of this axis.
    Review • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
    |
    Balversa (erdafitinib) • Lytgobi (futibatinib) • Pemazyre (pemigatinib)
    17d
    CLEAR trial: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov)
    P3, N=1069, Active, not recruiting, Eisai Inc. | Trial completion date: Jul 2024 --> Mar 2026
    Trial completion date
    |
    Keytruda (pembrolizumab) • sunitinib • everolimus • Lenvima (lenvatinib)
    17d
    Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, University of Chicago
    New P2 trial
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    18d
    Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis. (PubMed, Theranostics)
    Erdafitinib (Erda) was nano-sized and encapsulated in PLTs to construct nano-Erda@PLT... PLTs-camouflaged nano-vehicles enable nano-Erda-mediated tumor immunotherapy through the induction of pyroptosis. These findings introduce a novel approach in exploring nanomaterial-mediated pyroptosis for cancer immunotherapy.
    Journal • IO biomarker
    |
    CASP3 (Caspase 3) • GSDME (Gasdermin E)
    |
    Balversa (erdafitinib)
    18d
    TAS-120-203: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Taiho Oncology, Inc. | Trial primary completion date: Aug 2025 --> Mar 2024
    Trial primary completion date • Metastases
    |
    FGFR3 mutation • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion
    |
    Keytruda (pembrolizumab) • Lytgobi (futibatinib)
    19d
    Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. (PubMed, Front Pharmacol)
    Compared to RT + S, RT + L had good efficacy in the treatment of hepatocellular carcinoma with PVTT. Validation is needed in prospective studies with larger sample sizes.
    Retrospective data • Journal
    |
    AFP (Alpha-fetoprotein)
    |
    sorafenib • Lenvima (lenvatinib)
    19d
    Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report. (PubMed, Case Rep Oncol)
    To date, this patient continues to show a near complete response to this treatment regimen. To our knowledge, this is the first documented case of SMARCB1-deficient RMC without hemoglobinopathy to receive this treatment regimen and show such a response.
    Journal • Metastases
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    19d
    Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. (PubMed, World J Gastroenterol)
    BMI is a long-term predictor of the efficacy of lenvatinib plus camrelizumab, and obese/overweight patients have a better prognosis.
    Retrospective data • Journal • Metastases
    |
    AFP (Alpha-fetoprotein)
    |
    Lenvima (lenvatinib) • AiRuiKa (camrelizumab)
    19d
    Conversion therapy in advanced perihilar cholangiocarcinoma based on patient-derived organoids: A case report. (PubMed, World J Gastrointest Oncol)
    PDOs for drug sensitivity contribute to screening effective chemotherapy drugs for advanced pCCA, promoting conversion therapy and improving the prognosis.
    Journal • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • AFP (Alpha-fetoprotein)
    |
    cisplatin • gemcitabine • Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    19d
    Improving clinical outcomes of patients with hepatocellular carcinoma: Role of antiviral therapy, conversion therapy, and palliative therapy. (PubMed, World J Gastrointest Oncol)
    If, following downstaging, the patient qualifies for liver resection based on locally prevalent resectability criteria, then such therapy is labelled as conversion (from unresectable to resectable) therapy. In unresectable patients treated by a combination of treatment options, serological markers like neutrophil-to-lymphocyte ratio and alpha-fetoprotein are reported to predict treatment responses, thus enabling personalized medicine.
    Clinical data • Journal
    |
    AFP (Alpha-fetoprotein)
    |
    Lenvima (lenvatinib)
    19d
    Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer. (PubMed, Nat Rev Urol)
    The characterization of metastatic tumour samples can improve response prediction to immunotherapy, the anti-NECTIN4 antibody-drug conjugate enfortumab vedotin and the FGFR inhibitor erdafitinib. Routine metastatic biopsy can thus improve the precision of identifying driver druggable alterations, thus improving treatment selection for patients with mUC.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases • Biopsy
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR3 mutation • PD-L1 mutation
    |
    Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    20d
    Study on the Synergistic Mechanism of Photodynamic Therapy Combined With Ferroptosis Inducer to Induce Ferroptosis in Cholangiocarcinoma. (PubMed, Lasers Surg Med)
    Our findings suggest that Erastin or Lenvatinib can enhance the induction of ferroptosis in cholangiocarcinoma cells by photodynamic therapy by increasing intracellular ROS and inhibiting intracellular antioxidant pathways.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2)
    |
    GPX4 expression • SLC7A11 expression
    |
    Lenvima (lenvatinib) • erastin
    20d
    Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (clinicaltrials.gov)
    P3, N=480, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)
    21d
    Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer. (PubMed, Future Oncol)
    The side effects from taking futibatinib were manageable and similar in people with different types of cancer. To fully understand the safety of futibatinib, researchers will need to look at what side effects are reported in people taking futibatinib over a longer time in the real-world setting (outside of clinical trials).
    Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    Lytgobi (futibatinib)
    21d
    GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Tianjin Medical University Cancer Institute and Hospital | N=120 --> 80 | Trial primary completion date: Jan 2024 --> May 2024
    Enrollment change • Trial primary completion date • IO biomarker • Metastases
    |
    Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin